The biosimilar market was supposed to be simple: copy the molecule, undercut the price, capture the share. Instead, it’s become one of the most complex battlefields in pharma. At Octavus Consulting, we’ve spent the last two years helping clients navigate this chaos. Price erosion is inevitable, but profit erosion is optional. The winners are those […]

When a biotech misses its launch date, it’s rarely the science that fails – it’s the supply chain. In one 2024 case, a company developing a monoclonal antibody chose a CDMO solely based on cost per gram. Six months later, batch failures forced a rework that doubled expenses and delayed market entry by nearly a […]